Posted by Michael Wonder on 03 Oct 2018
Preliminary NICE ‘no’ for Takeda’s Alunbrig
3 October 2018 - Draft guidelines from the NICE do not recommend NHS funding for Takeda’s lung cancer drug Alunbrig.
The Institute is appraising the drug’s use to treat anaplastic lymphoma kinase positive advanced non-small-cell lung cancer in adults who have already had Pfizer’s Xalkori (crizotinib).
It concluded that clinical evidence based on single-arm studies suggests that people having Alunbrig (brigatinib) live longer than those having the standard of care after Xalkori, Novartis’ Zykadia (ceritinib), and that they live longer before their condition worsens.
